Monday, Jul 8, 2024 · SEC filings

What the smart money revealed on Jul 8

Real insider buys17insiders · $1.36M
Real insider sales23insiders · $337K
Fund 13Fs filed—not loaded for this day
Activist 13Ds filed—not loaded for this day

314 insider filings came in. We hid 53 planned (10b5-1) sellers and 204 people whose filings were routine, like grants and tax withholding.

trending_up

Global Acquisitions (AASP) President Ronald Boreta bought $598K

1.5M shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jul 3
$598K
trending_up

Global Acquisitions (AASP) Director John Boreta bought $598K

1.5M shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jul 3
$598K
trending_up

Tempest Therapeutics (TPST) President and CEO Stephen Brady bought $73.8K

35,000 shares on the open market. Not a grant or an option exercise.

Real buy Form 4 Traded Jul 3
$73.8K
trending_down

Bicycle Therapeutics (BCYC) CEO Kevin Lee sold $62.7K

Not marked as a planned 10b5-1 sale. Sold 1% of the shares they held directly. Still holds 384,076 shares.

Real sale Form 4 Traded Jul 3
$62.7K
trending_down

Joby Aviation (JOBY) Officer Matthew Field sold $60.8K

Not marked as a planned 10b5-1 sale. Sold 4% of the shares they held directly. Still holds 299,880 shares.

Real sale Form 4 Traded Jul 5
$60.8K
trending_down

G1 Therapeutics (GTHX) President and CEO John Bailey Jr. sold $19.2K

Not marked as a planned 10b5-1 sale. Sold 1% of the shares they held directly. Still holds 549,674 shares.

Real sale Form 4 Traded Jul 5
$19.2K
Show 14 more real buys
Show 20 more real sales
BCYC Bicycle Therapeutics · CTO Michael Skynner · Traded Jul 3
$19K
BCYC Bicycle Therapeutics · COO Alistair Milnes · Traded Jul 3
$19K
BCYC Bicycle Therapeutics · Chief Business Officer Nigel Crockett · Traded Jul 3
$19K
VPLM Voip-pal.com · CFO Jin Kuang · Traded Jul 1–5
$17K
BCYC Bicycle Therapeutics · Chief Scientific Officer Nicholas Keen · Traded Jul 3
$15.3K
GNLX Genelux · VP Yong Yu · Traded Jun 24
$14.5K
VPLM Voip-pal.com · Director Kevin Williams · Traded Jul 2–5
$13.4K
GNLX Genelux · General Counsel Sean Ryder · Traded Jun 24
$11.7K
GNLX Genelux · Head of Quality Caroline Jewett · Traded Jun 24
$10.5K
VPLM Voip-pal.com · Director Dennis Chang · Traded Jul 1–5
$10K
GTHX G1 Therapeutics · Chief Business Officer Mark Avagliano · Traded Jul 5
$6.62K
GWRS Global Water Resources · Director Andrew Cohn · Traded Jul 8
$6.41K
GTHX G1 Therapeutics · Chief Medical Officer Rajesh Malik · Traded Jul 5
$6.21K
GTHX G1 Therapeutics · COO Terry Murdock · Traded Jul 5
$6.21K
FIGS FIGS · Interim CFO Kevin Fosty · Traded Jul 3
$5.56K
BCYC Bicycle Therapeutics · Chief Prod and Supply Chain OFF Michael Hannay · Traded Jul 3
$4.83K
GTHX G1 Therapeutics · Chief Commercial Officer Andrew Perry · Traded Jul 5
$3.36K
BCYC Bicycle Therapeutics · Chief Accounting Officer Travis Thompson · Traded Jul 3
$2.91K
SILK Silk Road Medical · Chief Commercial Officer Andrew Davis · Traded Jul 3
$1.78K
GTHX G1 Therapeutics · CFO John Umstead · Traded Jul 5
$1.32K

13F season

Holdings as of Jun 30, 2024 are due Aug 14

54 funds have filed so far. 50 filed for the quarter before.

Biggest real insider buys, Jul 2–8

Open-market buys by officers and directors, filed in the 7 days up to Jul 8.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist